(Q64151300)
Statements
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension (English)
0 references
3 October 2019
0 references
31 March 2023
0 references
142
0 references
10 year
0 references
18 year
0 references